Russia: Deadlines for Authorized Representatives & Clinical Trial Compliance Extended to September 2027
Views:7
Time:2026-08-24 11:15:26


The Government of the Russian Federation has issued Government Resolution No. 974, amending the Rules for State Registration of Medical Devices. Two key compliance deadlines have been pushed back from September 2026 to September 2027. This transitional adjustment follows Russia’s shift to an electronic‑registry‑based medical‑device registration system and affects all foreign medical‑device manufacturers and clinical‑trial sponsors operating in Russia.




https://pharmvestnik.ru/content/news/pravitelstvo-rf-sdvinulo-sroki-obnovleniya-dannyh-ob-upolnomochennyh-predstavitelyah-medizdelii.html


一、Two Major Deadline Extensions



Both obligations have been postponed by 12 months:

(一)Compliance Confirmation for Clinical‑Trial Sites

Institutions intending to conduct medical‑device clinical trials on Russian territory must complete self‑assessment against the updated registration rules and submit notifications to Roszdravnadzor (Federal Service for Surveillance in Healthcare).

  • Old deadline: September 2026
  • New deadline: September 2027


(二)Registration‑filing for Foreign Manufacturers’ Authorized Representatives
All non‑resident medical‑device manufacturers must appoint a Russian‑based authorized representative or update existing representative filings to keep their products legally on the Russian market.
  • Old deadline: September 2026
  • New deadline: September 2027

The resolution is officially published and effective on Russia’s federal legal‑information portal.
二、Background: Buffer for the Electronic‑Registry Reform



This extension is part of Russia’s broader overhaul of medical‑device registration. Under Government Resolution No. 1684 dated 30 November 2024, new Rules for State Registration of Medical Devices entered into force, replacing paper‑based registration certificates with a fully electronic state registry system.

Roszdravnadzor has formally abolished formats for traditional paper medical‑device registration certificates and repealed related administrative documents. The one‑year grace period eases implementation pressure for market participants and prevents administrative bottlenecks and compliance risks from mass simultaneous submissions.

三、Compliance Recommendations for Export‑Oriented Medical‑Device Enterprises



While the regulator has granted extra time, companies targeting the Russian market are advised to prepare proactively:
Audit your authorized representative earlyReview the qualifications and filed records of your current Russian authorized representative against new‑rule requirements. Initiate replacement or supplementary documentation well in advance to avoid heavy administrative backlogs in late‑2027.
Monitor your clinical‑trial partners’ readiness:If you plan clinical trials in Russia, communicate closely with trial sites to track their progress on compliance confirmation, so site‑qualification issues do not delay your projects.
Follow ongoing regulatory updates:Detailed rules covering registry‑entry modifications, annual maintenance and compliance audits are still being finalized. Track official announcements or engage professional compliance service providers to maintain end‑to‑end regulatory compliance.
四、Closing Remarks



Russia’s medical‑device regulatory landscape is evolving rapidly, with frequent policy updates and increasingly granular compliance requirements. Wiselink will continue to monitor global regulatory changes and deliver practical interpretation and end‑to‑end compliance support for overseas‑going manufacturers. For further inquiries, please contact Wiselink.

Contact Us
Fill Form
Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.